Expression of the Bacillus anthracis protective antigen gene by baculovirus and vaccinia virus recombinants.

Infection and Immunity
L C Iacono-ConnorsJ M Dalrymple

Abstract

The gene encoding Bacillus anthracis protective antigen (PA) was modified by site-directed mutagenesis, subcloned into baculovirus and vaccinia virus plasmid transfer vectors (pAcYM1 and pSC-11, respectively), and inserted via homologous recombinations into baculovirus Autographa californica nuclear polyhedrosis virus or vaccinia virus (strains WR and Connaught). Expression of PA was detected in both systems by immunofluorescence assays with antisera from rabbits immunized with B. anthracis PA. Western blot (immunoblot) analysis showed that the expressed product of both systems was slightly larger (86 kilodaltons) than B. anthracis-produced PA (83.5 kilodaltons). Analysis of trypsin digests of virus-expressed and authentic PA suggested that the size difference was due to the presence of a signal sequence remaining with the virus-expressed protein. Immunization of mice with either recombinant baculovirus-infected Spodoptera frugiperda cells or with vaccinia virus recombinants elicited a high-titer, anti-PA antibody response.

References

Jan 1, 1987·Annual Review of Immunology·B Moss, C Flexner
May 1, 1986·Infection and Immunity·B E IvinsS H Leppla
Jan 1, 1986·Toxicon : Official Journal of the International Society on Toxinology·E J MachugaJ W Burnett
Mar 1, 1988·European Journal of Epidemiology·B E Ivins, S L Welkos
Jan 1, 1988·Methods in Enzymology·S H Leppla
Mar 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·W I WoodR M Lawn
Dec 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·G E SmithM D Summers
Aug 1, 1985·Infection and Immunity·B D GreenB E Ivins
Apr 1, 1966·Journal of General Microbiology·G G Meynell, E Meynell
Mar 1, 1968·Journal of Bacteriology·D C FishR E Lincoln
Aug 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·D Panicali, E Paoletti
Dec 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·M MackettB Moss
Jan 1, 1983·Infection and Immunity·P MikesellT M Dreier
Sep 1, 1983·Cell·M H Vodkin, S H Leppla
Jun 1, 1984·Vaccine·P HambletonJ Melling
Feb 1, 1960·Journal of General Microbiology·J L STANLEYH SMITH
Apr 1, 1962·American Journal of Public Health and the Nation's Health·P S BrachmanN R Ingraham

❮ Previous
Next ❯

Citations

Jul 21, 1999·Viral Immunology·A M BennettR W Titball
Jul 13, 2005·FEMS Immunology and Medical Microbiology·Gi-Eun RhieHee-Bok Oh
Sep 29, 2001·Journal of Applied Microbiology·L Baillie
Sep 1, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Stephen F Little
Jun 17, 2003·Cell Structure and Function·Toshihiro NagaminePrabhakara V Choudary
Aug 30, 2013·Expert Review of Vaccines·Manpreet KaurRakesh Bhatnagar
Dec 5, 2020·Cold Spring Harbor Protocols·Clara L KielkopfIna L Urbatsch
Aug 4, 2001·Biochemical and Biophysical Research Communications·N AhujaR Bhatnagar
Mar 2, 1999·Biochemical and Biophysical Research Communications·E AilorM J Betenbaugh
Dec 14, 1999·Microbes and Infection·S F Little, B E Ivins
Aug 1, 1991·Vaccine·P C Turnbull
Oct 19, 2006·Analytical Biochemistry·Mariusz Olczak, Teresa Olczak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.